Find Finafloxacin manufacturers, exporters & distributors on PharmaCompass

Finafloxacin

Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

1 NDC API

1 NDC API

FINISHED DOSAGE FORMULATIONS

1 FDF Dossiers, 1 FDA Orange Book

1 FDF Dossiers
1 FDA Orange Book

DIGITAL CONTENT

1 DATA COMPILATION #PharmaFlow, 1 NEWS #PharmaBuzz

media
1 DATA COMPILATION #PharmaFlow
1 NEWS #PharmaBuzz

MARKET PLACE

1 APIs

marketPlace
1 APIs

PATENTS & EXCLUSIVITIES

4 US Patents, 2 Health Canada Patents

patents
4 US Patents
2 Health Canada Patents

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

0 DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: 209342-40-5, Xtoro, Finafloxacin [inn], D26osn9q4r, Al-60371, Chebi:85176

Molecular Formula

C₂₀H₁₉FN₄O₄

Molecular Weight

398.4 g/mol

InChI Key

FYMHQCNFKNMJAV-HOTGVXAUSA-N

FDA UNII

D26OSN9Q4R

Finafloxacin is a fluoroquinolone antibiotic indicated in the treatment of acute otitis externa (swimmer's ear) caused by the bacteria Pseudomonas aeruginosa and Staphylococcus aureus. Finafloxacin is marketed by Novartis under the brand Xtoro, and was approved by the FDA in December 2014.

Finafloxacin is a Quinolone Antimicrobial.

1 2D Structure

Finafloxacin

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

7-[(4aS,7aS)-3,4,4a,5,7,7a-hexahydro-2H-pyrrolo[3,4-b][1,4]oxazin-6-yl]-8-cyano-1-cyclopropyl-6-fluoro-4-oxoquinoline-3-carboxylic acid

2.1.2 InChI

InChI=1S/C20H19FN4O4/c21-14-5-11-17(25(10-1-2-10)7-13(19(11)26)20(27)28)12(6-22)18(14)24-8-15-16(9-24)29-4-3-23-15/h5,7,10,15-16,23H,1-4,8-9H2,(H,27,28)/t15-,16-/m0/s1

2.1.3 InChI Key

FYMHQCNFKNMJAV-HOTGVXAUSA-N

2.1.4 Canonical SMILES

C1CC1N2C=C(C(=O)C3=CC(=C(C(=C32)C#N)N4CC5C(C4)OCCN5)F)C(=O)O

2.1.5 Isomeric SMILES

C1CC1N2C=C(C(=O)C3=CC(=C(C(=C32)C#N)N4C[C@H]5[C@H](C4)OCCN5)F)C(=O)O

2.2 Other Identifiers

2.2.1 UNII

D26OSN9Q4R

2.3 Synonyms

2.3.1 MeSH Synonyms

1. 3-quinolinecarboxylic Acid, 8-cyano-1-cyclopropyl-6-fluoro-7-((4as,7as)-hexahydropyrrolo(3,4-b)-1,4-oxazin-6(2h)-yl)-1,4-dihydro-4-oxo-

2. Xtoro

2.3.2 Depositor-Supplied Synonyms

1. 209342-40-5

2. Xtoro

3. Finafloxacin [inn]

4. D26osn9q4r

5. Al-60371

6. Chebi:85176

7. Finafloxacin (inn)

8. 8-cyano-1-cyclopropyl-6-fluoro-7-((4as,7as)-hexahydropyrrolo[3,4-b][1,4]oxazin-6(2h)-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic Acid

9. Bay35-3377

10. (-)-8-cyano-1-cyclopropyl-6-fluoro-7-((4as,7as)-hexahydropyrrolo(3,4-b)-1,4-oxazin-6(2h)-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic Acid

11. 7-[(4as,7as)-3,4,4a,5,7,7a-hexahydro-2h-pyrrolo[3,4-b][1,4]oxazin-6-yl]-8-cyano-1-cyclopropyl-6-fluoro-4-oxoquinoline-3-carboxylic Acid

12. Gastrochinolon

13. Gastroquinolone

14. 8-cyano-1-cyclopropyl-6-fluoro-7-[(4as,7as)-hexahydropyrrolo[3,4-b][1,4]oxazin-6(2h)-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic Acid

15. Xtoro (tn)

16. Finafloxacin [mi]

17. Unii-d26osn9q4r

18. Finafloxacin [who-dd]

19. Schembl1002869

20. Chembl1908370

21. Gtpl10809

22. Dtxsid10175096

23. Finafloxacin [orange Book]

24. Bcp23882

25. Zinc3985346

26. Al60371

27. Cs-5557

28. Db09047

29. Ncgc00510315-02

30. (-)-8-cyano-1-cyclopropyl-6-fluoro-7-((4as,7as)-hexahydropyrrolo(3,4-b)-1,4-oxazin-6(2h)-yl)-4-oxo-1

31. Ac-29291

32. Hy-13451

33. D10575

34. Q21011229

35. 3-quinolinecarboxylic Acid,8-cyano-1-cyclopropyl-6-fluoro-7-[(4as,7as)-hexahydropyrrolo[3,4-b]-1,4-oxazin-6(2h)-yl]-1,4-dihydro-4-oxo-

36. 7-[(4as,7as)-3,4,4a,5,7,7a-hexahydro-2h-pyrrolo[3,4-b][1,4]oxazin-6-yl]-8-cyano-1-cyclopropyl-6-fluoro-4-oxoquinoline-3-carboxylic Acid,hydrochloride

37. 8-cyano-1-cyclopropyl-6-fluoro-7-((1s,6s)-2-oxa-5,8-diazabicyclo[4.3.0]non-8-yl)-1,4-dihydro-4-oxo-3-quinolinecarboxylic Acid

38. 8-cyano-1-cyclopropyl-6-fluoro-7-[(4as,7as)-hexahydropyrrolo[3,4-b][1,4]oxazin-6(2h)-yl]-4-oxo-1,4-dihydro-3-quinolinecarboxylic Acid

2.4 Create Date

2006-10-26

3 Chemical and Physical Properties

Molecular Formula	C₂₀H₁₉FN₄O₄
Molecular Weight	398.4 g/mol
XLogP3	-0.7
Hydrogen Bond Donor Count	2
Hydrogen Bond Acceptor Count	9
Rotatable Bond Count	3
Exact Mass	398.13903326 g/mol
Monoisotopic Mass	398.13903326 g/mol
Topological Polar Surface Area	106 Å²
Heavy Atom Count	29
Formal Charge	0
Complexity	806
Isotope Atom Count	0
Defined Atom Stereocenter Count	2
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Drug and Medication Information

4.1 Drug Indication

Finafloxacin is indicated for the treatment of acute otitis externa (AOE) with or without an otowick, caused by susceptible strains of Pseudomonas aeruginosa and Staphylococcus aureus in patients age 1 year and older.

FDA Label

5 Pharmacology and Biochemistry

5.1 MeSH Pharmacological Classification

Anti-Bacterial Agents

Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)

Anti-Infective Agents, Urinary

Substances capable of killing agents causing urinary tract infections or of preventing them from spreading. (See all compounds classified as Anti-Infective Agents, Urinary.)

Topoisomerase II Inhibitors

Compounds that inhibit the activity of DNA TOPOISOMERASE II. Included in this category are a variety of ANTINEOPLASTIC AGENTS which target the eukaryotic form of topoisomerase II and ANTIBACTERIAL AGENTS which target the prokaryotic form of topoisomerase II. (See all compounds classified as Topoisomerase II Inhibitors.)

5.2 FDA Pharmacological Classification

5.2.1 Active Moiety

FINAFLOXACIN

5.2.2 FDA UNII

D26OSN9Q4R

5.2.3 Pharmacological Classes

Chemical Structure [CS] - Quinolones

5.3 Mechanism of Action

Finafloxacin is a fluoroquinolone antibiotic, which selectively inhibit bacterial type II topoisomerase enzymes, DNA gyrase and topoisomerase IV, which are required for bacterial DNA replication, transcription, repair and recombination.

NDC API